Terms ending in 2032
Every in-force patent on ImmunoGen, Inc.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,889,669 | Cytotoxic Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 9,169,272 | Cytotoxic Benzodiazepine Derivatives In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 9,840,564 | Cytotoxic Benzodiazepine Derivatives In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 10,179,818 | Cytotoxic Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US RE49,918 | Cytotoxic Benzodiazepine Derivatives In force · Low confidence | ImmunoGen, Inc. | In force | Low confidence | |
| US 9,156,854 | Novel Maytansinoid Derivatives with Sulfoxide Linker In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 9,428,543 | Preparation of Maytansinoid Antibody Conjugates by a One-Step Process In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 10,435,432 | Preparation of Maytansinoid Antibody Conjugates by a One-Step Process In force · High confidence | ImmunoGen Inc. | In force | High confidence | |
| US 11,744,900 | Preparation of Maytansinoid Antibody Conjugates by a One-Step Process In force · High confidence | ImmunoGen Inc. | In force | High confidence | |
| US 8,709,432 | Methods for Increasing Efficacy of FOLR1 Cancer Therapy In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| 5 more term ends in 2032 · Pro | |||||
10 of 15 patents shown. Soonest term end first, then patent number.
Pro members see all 15.
13 of these are in force and held by ImmunoGen, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.